<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0001845'>Inflammation</z:mp> is a factor in the aggravation of reperfusion injury after <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Since <z:chebi fb="11" ids="18295">histamine</z:chebi> H(2) receptor stimulation suppresses inflammatory reactions, effects of the central histaminergic activation on <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> were examined in rats </plain></SENT>
<SENT sid="2" pm="."><plain>Focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> for 2 h was provoked by transient occlusion of the right middle cerebral artery, and the <z:mpath ids='MPATH_124'>infarct</z:mpath> size was determined by 2,3,5-triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> stain after 24 h </plain></SENT>
<SENT sid="3" pm="."><plain>Effects of postischemic administration of thioperamide, an H(3) <z:chebi fb="68" ids="48706">antagonist</z:chebi>, and metoprine, an inhibitor of <z:chebi fb="11" ids="18295">histamine</z:chebi>-N-methyltransferase, were evaluated in rats treated with l-histidine, a precursor of <z:chebi fb="11" ids="18295">histamine</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, effects of these agents on changes in the striatal <z:chebi fb="11" ids="18295">histamine</z:chebi> level were examined by a microdialysis procedure </plain></SENT>
<SENT sid="5" pm="."><plain>Focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> provoked marked damage in rats treated with l-histidine (1000 mg/kg) alone </plain></SENT>
<SENT sid="6" pm="."><plain>Administration of l-histidine (1000 mg/kg) with either thioperamide (5 mg/kg) or metoprine (10 mg/kg) alleviated <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The size of <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> was 27% and 10% of that in animals treated solely with l-histidine, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>The combination treatment with thioperamide and metoprine decreased the size of <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> in rats given l-histidine (500 mg/kg), although protective effects were not clear without l-histidine </plain></SENT>
<SENT sid="9" pm="."><plain>A marked increase in the <z:chebi fb="11" ids="18295">histamine</z:chebi> concentration was observed in the histidine plus metoprine group, the value being 363% of that in the saline-injected group after 2-3 h </plain></SENT>
<SENT sid="10" pm="."><plain>The <z:chebi fb="11" ids="18295">histamine</z:chebi> concentrations in the histidine group and histidine plus thioperamide group were 188% and 248%, respectively </plain></SENT>
<SENT sid="11" pm="."><plain>These findings indicate that facilitation of central histaminergic activity reduced the <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> </plain></SENT>
</text></document>